Raphael Wekesa Lihana

Raphael Wekesa Lihana

Auto-generated profile, based on publicly available information

Raphael Wekesa Lihana

Centre for Virus Research, Kenya Medical Research Institute, Nairobi, Kenya

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2015 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
MWMark K. Webale
Mark K. Webale
VBValentine Budambula
Valentine Budambula
RLRaphael Lihana
Raphael Lihana
FOFrancis Ogollah
Francis Ogollah
ANAnthony K. Nyamache
Anthony K. Nyamache
TWTom Were
Tom Were
Information about HBV sero-markers, infection stages and genotypes in HIV-1 infected and uninfected injection and non-injection drug users (IDUs) in Kenya remains elusive. A cross-sectional study examining HBV sero-marker, infection stages and genotypes was conducted among HIV-1 infected and uninfected, respectively, IDUs (n = 157 and n = 214) and non-IDUs (n = 139 and n = 48), and HIV-1 uninfected non-drug using controls (n = 194) from coastal, Kenya. HBV sero-marker and infection stages were based on HBV 5-panel rapid test plasma sero-reactivity. DNA was extracted from acute and chronic plasma samples and genotypes established by nested-PCR and direct sequencing. HBsAg positivity was higher in HIV-1 infected IDUs (9.6 %) relative to HIV-1 uninfected IDUs (2.3 %), HIV-1 infected non-IDUs (3.6 %), HIV-1 uninfected non-IDUs (0.0 %) and non-drug users (2.6 %; P = 0.002). Contrastingly, HBsAb positivity was higher in HIV-1 uninfected IDUs (14.6 %) and non-IDUs (16.8) in comparison to HIV-1 infected IDUs (8.3 %), and non-IDUs (8.6 %), and non-drug users (8.2 %; P = 0.023). HBcAb positivity was higher in HIV-1 infected IDUs (10.2 %) compared to HIV-1 uninfected IDUs (3.3 %), HIV-1 infected non-IDUs (6.5 %), HIV-1 uninfected non-IDUs (2.1 %) and non-drug users (4.6 %; P = 0.038). Acute (5.7 %, 1.4 %, 0.0 %, 0.0 % and 1.5 %) and chronic (5.1 %, 0.9 %, 3.6 %, 0.0 % and 1.5 %) stages were higher in HIV-1 infected IDUs, compared to HIV-1 uninfected IDUs, HIV-1 infected and uninfected non-IDUs and non-drug users, respectively. However, vaccine type response stage was higher in HIV-1 uninfected IDUs (15.4 %) relative to HIV-1 infected IDUs (6.4 %), and HIV-1 infected (6.5 %), and uninfected (10.4 %) non-IDUs, and non-drug users (5.7 %; P = 0.003). Higher resolved infection rates were also recorded in HIV-1 uninfected IDUs (11.2 %) compared to HIV-1 infected IDUs (8.3 %), and HIV-1 infected (7.2 %), uninfected (6.3 %) non-IDUs, and non-drug users (6.7 %; P = 0.479), respectively. Only A1 genotype showing minimal diversity was detected among the study participants. HBV sero-markers and infection staging are valuable in diagnosis and genotyping of HBV infections. Among IDUs, higher HBsAg and HBcAb positivity in HIV-1 infected and higher HBsAb positivity in HIV-1 negative IDUs suggests frequent exposure. Additionally, HBV genotype A is the dominant circulating genotype in both high and low risk populations of Kenya.

1 January 2013 in AIDS Research and Therapy
Verified
Journal Article
Open access
PDF file
EBErick M Bosire
Erick M Bosire
ANAnthony K Nyamache
Anthony K Nyamache
MGMichael M Gicheru
Michael M Gicheru
Samoel Ashimosi KhamadiSamoel Ashimosi Khamadi
Samoel Ashimosi Khamadi
RLRaphael W Lihana
Raphael W Lihana
VOVincent Okoth
Vincent Okoth
The enumeration of absolute CD4 counts is of primary importance for many medical conditions especially HIV infection where therapeutic initiation depends on the count. These ranges tend to vary across populations. However, these ranges have not been comprehensively established in the Kenyan population. Therefore, this study aimed at establishing the reference ranges for the CD4 and CD8 T-lymphocytes in normal healthy individuals in Kenya.

4 November 2013 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
MKMichael Kiptoo
Michael Kiptoo
JBJames Brooks
James Brooks
RLRaphael W Lihana
Raphael W Lihana
PSPaul Sandstrom
Paul Sandstrom
ZNZipporah Ng’aNg’a
Zipporah Ng’aNg’a
ESElijah M Songok
Elijah M Songok
Access to antiretroviral therapy (ART) has increased dramatically in Sub-Saharan Africa. In Kenya, 560,000 people had access to ART by the end of 2011. This scaling up of ART has raised challenges to the Kenyan health system due to emergence of drug resistant viruses among those on treatment and possible onward transmission. To counter this, and come up with an effective treatment strategy, it has become vital to determine baseline mutations associated with drug resistance among the circulating strains of HIV-1in Kenya.

30 December 2009 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
RLRaphael W Lihana
Raphael W Lihana
Samoel Ashimosi KhamadiSamoel Ashimosi Khamadi
Samoel Ashimosi Khamadi
RLRaphael M Lwembe
Raphael M Lwembe
JKJoyceline G Kinyua
Joyceline G Kinyua
JMJoseph K Muriuki
Joseph K Muriuki
ESElijah M Songok
Elijah M Songok
Infection with HIV-1 is characterized by genetic diversity such that specific viral subtypes are predominant in specific geographical areas. The genetic variation in HIV-1 pol and env genes is responsible for rapid development of resistance to current drugs. This variation has influenced disease progression among the infected and necessitated the search for alternative drugs with novel targets. Though successfully used in developed countries, these novel drugs are still limited in resource-poor countries. The aim of this study was to determine HIV-1 subtypes, recombination, dual infections and viral tropism of HIV-1 among Kenyan patients prior to widespread use of antiretroviral drugs.

15 June 2015 in Current HIV Research
Verified
Journal Article
Closed access
PDF file
RKRukia M. Kibaya
Rukia M. Kibaya
RLRaphael W. Lihana
Raphael W. Lihana
MKMichael Kiptoo
Michael Kiptoo
ESElijah M. Songok
Elijah M. Songok
ZNZipporah Ng’aNg’a
Zipporah Ng’aNg’a
RLRaphael M. Lwembe
Raphael M. Lwembe
Background: Hepatitis B (HBV) and Human Immunodeficiency virus (HIV) are both bloodborne viruses. Markers of either active or past HBV infection are present in many HIV infected patients. Worldwide, HBV prevalence varies geographically and endemicity is classified as low (8%). Genotypically, prevalence varies among different populations, with genotype A having a wide distribution. In Kenya, the prevalence of HIV-1/HBV co-infection ranges from 6-53% depending on the sub-population, with genotype A as the most common. Objective: To determine the prevalence and characterize HBV in HBV/HIV co-infected injecting drug users (IDUs) from Mombasa, Kenya. Methods: Blood samples were collected from HIV-infected IDUs in Mombasa, Kenya. Hepatitis B surface antigen (HBsAg) was tested by enzyme immunoassay (EIA). HBV DNA was extracted by SMITEST R&D kit. Polymerase chain reaction (PCR) was done; followed by population sequencing of HBV preS, core and full genome using specific primers. Analysis was done phylogenetically with reference sequences from the Genbank. Results: Seventy two HIV-positive samples were collected from IDUs in Mombasa in February and March 2010. Of these, 10 (13.89%) were HBsAg-positive by EIA. Nine of the 10 samples (12.5%) were PCR positive for HBV in the preS region; from these, four HBV full length sequences were obtained. Phylogenetic analysis showed that all belonged to genotype A1. Conclusion: The prevalence of HBV co-infection among HIV-infected IDUs in Mombasa, Kenya was 12.5%. Phylogenetically, sequences obtained from this study showed clusters that were distinct from reported Kenyan reference sequences from the Genbank. The findings point to an existence of a transmission network among IDUs in Mombasa. This further suggests that HBV genotypes in Kenya may be regionally diverse.

17 May 2017 in The East African Health Research Journal
Verified
Journal Article
Open access
PDF file
DMDuncan Ndegwa Maina
Duncan Ndegwa Maina
ANAndrew Kimanga Nyerere
Andrew Kimanga Nyerere
RGRuth Wambui Gicho
Ruth Wambui Gicho
JMJoseph Maina Mwangi
Joseph Maina Mwangi
RLRaphael Wekesa Lihana
Raphael Wekesa Lihana
Background: Hepatitis B virus (HBV) and hepatitis C virus (HCV) are among the most chronic viral infections worldwide. Co-infections with HBV and HCV have become increasingly common among people living with HIV, resulting in a growing public health concern. The primary aim of our study was to determine the prevalence of HBV and HCV and their associated factors among HIV-1-infected patients attending the Ngong Sub-County Hospital comprehensive care clinic. Methods: After providing consent, a 5 mL blood sample was collected from each study participant visiting the comprehensive care clinic. The blood was screened for hepatitis B surface antigen and HCV antibodies using chemiluminescence immunoassay test according to the manufacturer’s instructions. The CD4 T-cell counts were determined using FACSCalibre machine, while HIV-1 viral load was determined using the Abbott m2000rt System according to the manufacturer’s instructions. A questionnaire was used to collect sociodemographic information and data on factors associated with HBV and HCV co-infections. Results: One hundred and ninety HIV-1-infected patients participated in this study: 150 (78.9%) women and 40 (21.1%) men. In the overall study population, the prevalence of HBV co-infection was 5.8% (95% CI, 2.6%–8.9%) and of HCV co-infection was 4.2% (95% CI, 1.6%–7.4%). However, no individual was co-infected with all 3 viruses. HCV was associated with antiretroviral treatment (OR 0.2; 95% CI, 0.0–0.8; P=.036), while HBV showed a significant association with condom usage (OR 0.3; 95% CI, 0.1–0.9; P=.039) and median viral load. Conclusions: A high prevalence of HIV/HBV and HIV/HCV co-infection was reported in this study, suggesting that HIV-infected patients should be routinely screened for HBV and HCV infections, and preventive and control measures should be put in place that include public education on HBV and HCV infections.